Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia

Lee, S; Tallman, Martin S.; Oken, MM; Cassileth, Peter A.; Bennett, John M.; Ph, Wiernik; Rowe, Jacob M.

doi:10.1038/sj.leu.2401853

Cited by 29 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…subjects experienced a longer second progression-free survival (PFS2) after vaccine therapy compared to the PFS after previous chemotherapy (PFS1)] in response to OCDC vaccination. PFS is important in assessing studies of novel chemotherapy or immunologic treatment strategies for patients with relapsed disease, and was first used was first used by Lee et al to predict PFS2 in patients with relapsed acute myeloid leukemia (23) (Figure 4C). As the historic remission inversion rate (PFS2 > PFS1) in ovarian cancer is 3% (24), these result are encouraging given the propensity of recurrent ovarian cancer to commonly recur in shorter intervals than the previous remission interval.…”

Section: Resultsmentioning

confidence: 99%

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

Chiang

Kandalaft

Tanyi

et al. 2013

Clinical Cancer Research

190

211

View full text Add to dashboard Cite

Purpose: Whole tumor lysates are promising antigen sources for dendritic cell (DC) therapy as they contain many relevant immunogenic epitopes to help prevent tumor escape. Two common methods of tumor lysate preparations are freeze-thaw processing and UVB irradiation to induce necrosis and apoptosis, respectively. Hypochlorous acid (HOCl) oxidation is a new method for inducing primary necrosis and enhancing the immunogenicity of tumor cells.Experimental Design: We compared the ability of DCs to engulf three different tumor lysate preparations, produce T-helper 1 (T H 1)-priming cytokines and chemokines, stimulate mixed leukocyte reactions (MLR), and finally elicit T-cell responses capable of controlling tumor growth in vivo.Results: We showed that DCs engulfed HOCl-oxidized lysate most efficiently stimulated robust MLRs, and elicited strong tumor-specific IFN-g secretions in autologous T cells. These DCs produced the highest levels of T H 1-priming cytokines and chemokines, including interleukin (IL)-12. Mice vaccinated with HOCl-oxidized ID8-ova lysate-pulsed DCs developed T-cell responses that effectively controlled tumor growth. Safety, immunogenicity of autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC vaccine), clinical efficacy, and progression-free survival (PFS) were evaluated in a pilot study of five subjects with recurrent ovarian cancer. OCDC vaccination produced few grade 1 toxicities and elicited potent T-cell responses against known ovarian tumor antigens. Circulating regulatory T cells and serum IL-10 were also reduced. Two subjects experienced durable PFS of 24 months or more after OCDC.Conclusions: This is the first study showing the potential efficacy of a DC vaccine pulsed with HOCloxidized tumor lysate, a novel approach in preparing DC vaccine that is potentially applicable to many cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

Chiang

Kandalaft

Tanyi

et al. 2013

Clinical Cancer Research

190

211

View full text Add to dashboard Cite

show abstract

“…Even when a second complete remission (cr2) in aml is obtained, its duration is often shorter than that for the first complete remission (cr1), and overall survival (os) rates are quite low-in the range of 11%-19% at 5 years 29,[15][16][17]24 . Because the chance of relapsing after consolidation chemotherapy is high-of patients who did not undergo transplantation in cr1 in three Medical Research Council trials, more than 30% relapsed 16 -and because ahsct after relapse is the only treatment that can potentially cure a patient with aml 20,25-27 , the classification of relapsed patients into risk groups to predict outcome after ahsct would be useful.…”

Section: Datamentioning

confidence: 99%

Characteristics Predicting Outcomes of Allogeneic Stem-Cell Transplantation in Relapsed Acute Myelogenous Leukemia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, for patients entering in complete remission (CR), relapse occurs in more than 50% of cases [1]. Relapsed=refractory (R=R) AML patients have a very dismal outcome with approximately 10% of patients surviving [2,3]. The most important predictors of response to salvage chemotherapy are age, karyotype, duration of first remission, and history of previous hematopoietic stem cell transplantation (HSCT) [3].…”

Section: Introductionmentioning

confidence: 99%

5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

et al. 2013

View full text Add to dashboard Cite

Despite progress in the understanding of leukemia pathophysiology, the treatment of acute myeloid leukemia (AML) remains challenging. In patients with refractory or relapsed (R=R) AML, the prognosis is still poor and this group is targeted for new drug development. We reviewed the outcome of 47 patients, with R=R AML after at least one course of intensive chemotherapy, treated with 5-azacytidine in three different French institutions. The overall response rate was 38% including complete remission in 21%, partial remission in 11%, and hematological improvement in 6% of cases. Median time to relapse was 6 (range, 1-39) months. Median overall survival was 9 months (not reached by responders vs. 4.5 months for nonresponders patients, P 5 0.0001). Univariate analysis identified the absence of peripheral blood blasts and <20% bone marrow blasts as prognostic factors for both overall response and survival, but not age, ECOG=PS, type of AML, cytogenetic, status of the disease, number of previous lines of therapy, previous hematological stem cell transplantation, or white blood cells count. Bone marrow blasts percentage <20% was the only independent prognostic factor identified by multivariate analysis for overall response (P 5 0.0013) and survival (P 5 0.0324). Six patients in remission could proceed to an allogenic hematological stem cell transplantation. The drug-related grade 3=4 adverse events were hematopoietic toxicities (38%) and infection (32%). In conclusion, this study suggests that a salvage therapy with 5-azacytidine is an interesting option for patients with R=R AML after intensive chemotherapy. Prospective randomized studies are needed to demonstrate a superiority of this approach over others strategies. Am. J. Hematol. 88:601-605,

show abstract

Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia

Cited by 29 publications

References 31 publications

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

Characteristics Predicting Outcomes of Allogeneic Stem-Cell Transplantation in Relapsed Acute Myelogenous Leukemia

5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

Contact Info

Product

Resources

About